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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the clinical, economic and humanistic health outcomes of non-medical prescribing for managing acute and chronic health
conditions in primary and secondary care settings compared with medical prescribing.
B A C K G R O U N D
Description of the health care challenge
A range of health workforce strategies are needed to address is-
sues of health service access and efficiency. In developed countries,
the increasing demand for health services arises from an ageing
population and the resultant increasing burden of chronic disease
(Bhanbhro 2011; Duckett 2005; Phillips 2008; WHO 2012).
Increased health demands can be met in part by task substitution
within the health workforce. One health workforce strategy for
task substitution is to permit prescribing by healthcare providers
other than medical staff (doctors or dentists). Non-medical pre-
scribers may include nurses, pharmacists, allied health profession-
als and physician assistants. Extending a health provider’s scope of
practice, including the right to prescribe, has been supported in a
number of countries as a means of benefiting patient care by the
effective use of health professionals’ skills, improving patient ac-
cess to timely care, improving patient choice and enhancing team-
work and better use of resources (Department of Health 1999;
Ellis 2006; Hooker 2006; Stewart 2010).
The devolution of prescribing rights in developed countries has
continued from a historical base in the United States of America
(USA) in the 1970s through to more recent government led re-
forms in the United Kingdom (UK), Canada, the Netherlands,
New Zealand and Australia. While the definition of prescribing
may vary between countries for the purpose of our review pre-
scribing is defined as “an iterative process involving the steps of
information gathering, clinical decision making, communication,
and evaluation that results in the initiation, continuation or cessa-
tion of a medicine” (AustralianNational HealthWorkforce 2010).
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The term ’medical prescribing’ is prescribing by medically quali-
fied doctors. Prescribing by dentists is excluded from the defini-
tion of ’medical prescribing’ and this review. The supply of non-
prescription (over-the-counter) medicines by pharmacists or phar-
macy assistants working in community pharmacies is excluded
from our definition of prescribing. The term ’non-medical pre-
scribing’ originates from theUK,where it is defined as “prescribing
by specially trained nurses, optometrists, pharmacists, physiother-
apists, podiatrists and radiographers, working within their clinical
competence as either independent or supplementary prescribers”
(National Prescribing Centre 2012).
Supplementary prescribing which was introduced in 2003, is de-
fined as “a voluntary partnership between an independent pre-
scriber (a doctor or dentist) and a supplementary prescriber (e.g.
nurse, optometrist, pharmacist, physiotherapist, chiropodist/po-
diatrist and radiographer) to implement an agreed patient-spe-
cific Clinical Management Plan with the patient’s agreement”
(Department of Health 2003). Non-medical prescribing rights
were extended in 2006 with the introduction of independent pre-
scribing. The UK Department of Health defines independent
prescribing as “prescribing by a practitioner (e.g. doctor, dentist,
nurse, pharmacist, and optometrist) responsible and accountable
for the assessment of patients with undiagnosed or diagnosed con-
ditions and for decisions about the clinical management required,
including prescribing”. Independent prescribing is one element
of the clinical management of a patient and occurs in partner-
ship with the patient. It requires an initial patient assessment, in-
terpretation of that assessment, a decision on safe and appropri-
ate therapy, and a process for ongoing monitoring. The indepen-
dent prescriber is responsible and accountable for at least this ele-
ment of a patient’s care. (Department of Health 2006). Indepen-
dent prescribing does not require a Clinical Management Plan.
From 1May 2006, nurse and pharmacist independent prescribers
who completed the appropriate training could prescribe, with a
few exceptions, any licensed medicine for any medical condition
within their competence. In 2009, independent prescribing rights
were extended to include unlicensed medicines. While prescrib-
ing of controlled drugs was restricted, this limitation was removed
through legislative change in April 2012 (Home Office 2012).
In the USA, devolution of prescribing authority varies from State
to State. Collaborative Practice Agreements in 46 States allow a
pharmacist to partner with a physician to manage a number of
health services, includingdrug therapy (Law 2013;Thomas 2006).
Physician assistants and nurse practitioners were introduced in
1967 to support medical care. These practitioners undertake a
range of clinical functions including prescribing (Hooker 2006).
Within Canada, a pharmacist’s scope of prescribing practice varies
between the provinces from independently prescribing to adapt-
ing (modifying) or continuing prescriptions (Law 2012). A col-
laborative prescribing model has emerged as the preferred model
of practice within New Zealand and Australia. Collaborative pre-
scribing is undertaken within a multidisciplinary team and can
include the continuum of prescribing from transcription of orders
(with or without medical signature), prescribing specified drugs
and doses by protocol, prescribing by clinical management plan
(allowing choice of drugs and doses) to independent prescribing
where a prescribing consultation with a medical practitioner is not
required (Weeks 2008; Wheeler 2012). Health Workforce Aus-
tralia has recently developed a pathway for non-medical prescrib-
ing. Prescribing models emphasise team communication and are
divided into autonomous prescribing, prescribing under super-
vision and prescribing via a structured prescribing arrangement
(Health Workforce Australia 2013). As part of the reform pro-
cess health agencies in Australia, Canada, New Zealand and the
UK have developed prescribing competency frameworks for non-
medical health professionals (National Prescribing Centre 2012;
National Prescribing Service 2012; Pharmacy Council of New
Zealand 2013; Yuksel 2008).
Description of the intervention
For the purpose of our review the term ’non-medical prescribing’
will be used to cover the prescribing of medicines by a broad range
of healthcare providers other than doctors and dentists, prescrib-
ing in primary or secondary care. No limitation is set on the type
of non-medical health care provider undertaking prescribing nor
the scope of their prescribing practice. Our review looks at pre-
scribing, which as per our definition is much broader than issuing
a prescription. Frequently, non-medical prescribing is done in col-
laboration or partnership with doctors, and within this practice
there are different models of prescribing. Our review may cover
degrees of substitution and supplementation.
The role of non-medical prescribers in the secondary care settings
may involve supporting acute or chronic care by prescribing in a
timely way medication on admission, discharge or where there is a
specialist need e.g. total parenteral nutrition. Specialist outpatient
clinics managed by non-medical health professionals may exist in
either the primary or secondary care setting e.g. for the manage-
ment of hypertension, lipids, diabetes and pain. In primary care
settings, prescribing may be undertaken by nurses or other health-
care providers caring for patients in their homes or through in-
volvement with general practice teams, community health centres,
mental health teams or community pharmacies.
How the intervention might work
Non-medical prescribing has developed as an accepted health care
policy in a number of countries to improve access to health care,
to better use the skills of doctors who can focus on more acute
patient needs, to better use the skills of pharmacists, nurses and
other health providers, to potentially reduce costs for achieving
the same or better health outcomes for consumers, and to re-
tain health workers by increasing job satisfaction (Department
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of Health 1999; Tonna 2007). While qualitative studies support
non-medical prescribing from a patient and practitioner perspec-
tive, robust evidence is required of clinical, economic and human-
istic outcomes. It is noted that where non-medical prescribers are
practicing in collaborative teams it may be difficult to apportion
the impact of the non-medical prescriber on the primary and sec-
ondary outcomes of this review. Wider adoption of non-medical
prescribing practice in developed countries frequently faces local
regulatory hurdles and opposition from the medical establishment
which has raised concerns about professional autonomy, patient
safety, the diagnostic competency of non-medical prescribers and
costs (Cooper 2008). Evidence that patient outcomes arising from
non-medical prescribing are equivalent or better than doctors will
provide a basis for policymakers to support wider implementation
of this practice outside of the UK.
Why it is important to do this review
It is important for health practitioners and policy makers to un-
derstand the evidence existing for non-medical prescribing to ad-
dress access or health workforce needs. This information will also
guide future decision making with regards to implementing or ex-
panding non-medical prescribing.
Potential beneficiaries of the findings include:
• policy makers seeking to use workforce resources more
efficiently;
• policy makers seeking to improve health systems in primary
and secondary care;
• policy makers seeking to meet a clinical need;
• policy makers and consumers seeking evidence of safe and
effective practice;
• consumers seeking greater choice and easier access to
medicines;
• non-medical health professionals seeking to better utilise
their skills and/or extend their scope of practice;
• medical staff seeking to focus on patients with the greatest
medical need; and
• researchers interested in evaluating non-medical prescribing.
Despite gradual rolling out of reforms, the evidence for the poten-
tial benefits of non-medical prescribing from well controlled trials
involving a wide range of health professionals requires identifica-
tion, synthesis and evaluation. Several narrative reviews of the non-
medical prescribing literature have been undertaken (Australian
National Health Workforce 2010; Kay 2004; Tonna 2007), and
the British government commissioned two evaluations covering
supplementary and independent prescribing (Bissell 2008; Latter
2010).
A Cochrane systematic review on substitution of doctors by nurses
in primary care cautiously found substitutionof doctors in primary
care with suitably trained nurses can produce as high a quality of
care and as good health outcomes with no appreciable difference
between doctors and nurses in resource utilisation outcomes asso-
ciated with prescribing (Laurant 2004). The review was limited to
nurses in the primary care setting as first contact or ongoing care
for undifferentiated patients.
A further Cochrane review “found that the question of whether
pharmacists canmanage drug therapy as well as physicians remains
unanswered due to a shortage of studies” (Benney 2000). The re-
view found a single randomised controlled trial (RCT) of pharma-
cist managed drug therapy including prescribing drugs (Hawkins
1979), which demonstrated some improvement in process out-
comes but there was no big difference in patient outcomes.
Against this background, we seek to systematically identify, review
and update the evidence from controlled studies and uncontrolled
studies (e.g. interrupted time series (ITS) studies) on the clinical,
humanistic and economic outcomes of non-medical prescribing
in primary and secondary care settings. This review will also con-
sider any adverse effects of non-medical prescribing which may be
clinical (e.g. deterioration in care or incidence of adverse drugs re-
actions), economic (e.g. increased treatment costs) or humanistic
(e.g. decreased patient satisfaction).
The proposed review will cover a wider range of healthcare
providers undertaking non-medical prescribing; span primary and
secondary care settings and consider acute and chronic prescribing
situations.
O B J E C T I V E S
To assess the clinical, economic and humanistic health outcomes
of non-medical prescribing for managing acute and chronic health
conditions in primary and secondary care settings compared with
medical prescribing.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include studies of patients or health professionals or
healthcare settings using the definitions of designs outlined in the
Cochrane Effective Practice and Organisation of Care (EPOC)
Group checklist (Cochrane EPOCGroup 2002). We will include
RCTs and cluster-randomised trials, non-RCTs where investiga-
tors have allocated participants to the different groups that are
being compared using a method that is not random but where at
least two groups with interventions are followed, controlled be-
fore-after (CBA) studies with at least two intervention sites and
two control sites, and ITS studies, with at least three observations
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before and after the intervention. We will include qualitative stud-
ies that are linked to quantitative studies and where qualitative
analysis methods have been applied. We will exclude qualitative
studies alone as the primary focus is on clinical outcomes.
Types of participants
Healthcare providers who are not medical doctors or dentists,
undertaking prescribing including, nurses, optometrists, pharma-
cists, physician assistants and other allied health professionals or
categories not specifically mentioned whose roles meet our defini-
tion of non-medical prescribing.
Setting
We will include studies based in any primary care or hospital
setting where non-medical prescribing occurs.
Types of interventions
We will include studies involving the health providers other than
doctors undertaking prescribing according to our definition of
prescribing. We will exclude studies involving the supply function
alone of pharmacists including over-the-counter products.Wewill
exclude studies only involving subjective outcomes not linked to
quantitative measures.
We will include the following six comparisons for non-medical
prescribing in acute and chronic care:
1. non-medical prescribing versus medical prescribing in acute
care;
2. non-medical prescribing versus medical prescribing in
chronic care;
3. non-medical prescribing versus medical prescribing in
secondary care;
4. non-medical prescribing versus medical prescribing in
primary care;
5. comparisons between different non-medical prescriber
groups;
6. non-medical healthcare providers with formal prescribing
training versus those without formal prescribing training.
Types of outcome measures
We anticipate the studies included in the review would report a
wide variety of outcome measures. We will only include studies
with objective measures of patient outcomes. Non-inferiority will
be regarded as a positive outcome where a non-medical prescribing
outcome is at least as good as the comparator. We will exclude
studies reporting only economic or humanistic outcomes without
clinical outcomes.
Primary outcomes
Clinical outcomes
Patient outcomes
We will use standard outcome measures covering health and well-
being including physiological measures of treatment such as blood
pressure, lipid control into dichotomous and continuous outcomes
e.g. dichotomous outcomes will include the proportion of patients
with improved disease management or markers of disease.
We will also consider the following outcomes:
• proportion of prescribers, medical and non-medical,
appropriately adhering to practice guidelines;
• proportion of patients demonstrating treatment adherence;
• proportion of patients and items appropriately prescribed
or deprescribed;
• patient satisfaction where measured by a validated tool and
part of an effectiveness study;
• non-medical prescriber versus medical prescriber waiting
time to care;
• non-medical prescribers adversely effecting the health
outcomes of patients through medication errors, prescribing
errors, adverse effects, wrong diagnoses or treatment, increased
hospitalisations or representations for medical care.
Secondary outcomes
Economic outcomes
Resource use
• Medical time saved by non-medical prescribers
• Non-medical prescriber versus medical prescriber
prescription volume and cost, patient out of pocket expenses,
service costs, deprescribing rate and cost
• Differential effects across advantaged and disadvantaged
populations based on place of residence or socio-economic status
• Increased resource use
Humanistic outcomes
We will include patient reported outcomes of knowledge require-
ments, daily functioning and validated measures of quality of life.
We will include non-medical prescriber outcomes of job satisfac-
tion, skills utilisation, education needs and workload effects.
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Search methods for identification of studies
Electronic searches
We will search the following databases:
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (EBM Reviews, OvidSP);
• Health Technology Assessment (HTA) (EBM Reviews,
OvidSP);
• NHS Economic Evaluation Database (EED) (EBM
Reviews, Ovid SP);
• MEDLINE (1946-, In-Process and other non-indexed
citations) (OvidSP);
• EMBASE (1980-)- (OvidSP);
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (1980-) (EBSCOhost);
• International Pharmaceutical abstracts (IPA);
• PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/);
• ProQuest Dissertations & Theses Full Text;
• Science Citation Index Expanded (SCI-EXPANDED)
(1900-present) (Web of Science);
• Social Sciences Citation Index (SSCI) (1900-present) (Web
of Science);
• Conference Proceedings Citation Index-Science (CPCI-S)
(1990-present) (Web of Science);
• Conference Proceedings Citation Index-Social Science &
Humanities (CPCI-SSH) (1990-present) (Web of Science).
The MEDLINE search strategy as illustrated in Appendix 1 was
developed by the Cochrane Effective Practice and Organisation of
Care (EPOC) Group Trials Search Co-ordinator in consultation
with the authors. We will translate it for other databases using ap-
propriate syntax and vocabulary for those databases. We will em-
ploy the Cochrane Highly Sensitive Search Strategy (sensitivity-
and precision-maximizing version, 2008 revision) to identify ran-
domised trials, and the Cochrane EPOC Group methodology fil-
ter to identify non-randomised studies. We will manage search re-
sults using referencemanagement softwares and remove duplicates
before screening is undertaken. We will also search the Cochrane
Database of Systematic Reviews (CDSR) and the Database of Ab-
stracts of Reviews of Effects (DARE) for related systematic reviews.
Searching other resources
Grey literature
We will conduct a grey literature search to identify studies not
indexed in the databases listed above. We will use the following
sources:
• OpenGrey (http://www.opengrey.eu/);
• Grey Literature Report by the New York Academy of
Medicine (http://www.greylit.org/);
• Agency for Healthcare Research and Quality (AHRQ) (
http://www.ahrq.gov/).
We will report any additional sites searched in the full review.
Trial registries
We will search one or both of the following registries:
• the Word Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) search portal (http://
apps.who.int/trialsearch/);
• ClinicalTrials.gov (http://clinicaltrials.gov/).
We will report the corresponding search terms and numbers of
results in the full review.
Other resources
• Screen individual journals and conference proceedings (e.g.
handsearching)
• Review reference lists of all included studies, relevant
systematic reviews; reference lists of other publications will be
undertaken if required
• Contact authors of relevant studies or reviews when
necessary to clarify reported published information or to seek
unpublished results or data
• Contact researchers with expertise relevant to the review
topic/EPOC interventions
• Conduct cited reference searches for all included studies in
citations indexes
We will document additional sources, if any, in the final review.
Data collection and analysis
Selection of studies
We will merge the search results through the use a reference man-
agement software and remove duplicate records. Two review au-
thors (GW, JG) will then independently assess the titles and ab-
stracts of the search results to evaluate their potential eligibility,
and discuss articles that are clearly irrelevant to the topic. The two
review authors will not be responsible for the selection of studies
they were involved in or associated with. Neutral members of the
review team will be in-charge of assessing the eligibility of each
study for inclusion in the review. We will retrieve full text of all
remaining relevant papers and the two review authors will assess
these full-text articles independently based on the review’s inclu-
sion criteria. We will include a ’Characteristics of excluded studies’
table in the review. This table will include studies that appear to
meet inclusion criteria but were eventually excluded and we will
report the reasons for exclusion e.g. not an RCT, insufficient ob-
servations for an ITS study, only one intervention and or control
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site for a CBA study, a multifaceted intervention. If there is un-
certainty or disagreement, consensus will be reached by discussion
with other review authors. We will correspond with authors of in-
cluded studies if necessary to obtain further information in order
to assess compliance with eligibility and confirm data. Within the
review we will map the flow of information of identified, included
and excluded studies by depicting them in a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram.
Data extraction and management
Wewill use a standard data extraction form based on theCochrane
EPOCGroup’s data collection checklist (Cochrane EPOCGroup
2002). We will design and assess the form to suitably extract data
on the characteristics of each study including study design, study
participants, the interventions and comparators, outcomes and
follow-up periods, funding source and interest declarations. Two
authors (GW, JG) will extract independently study characteristics
and outcome data outlined above. We will check the data against
each other. If there is uncertainty or disagreement, we will reach
consensus by discussion or in the presence of an adjudicating third
author, if necessary. We will contact study authors to obtain any
missing information. If studies are reported in more than one
publication, we will extract the data from all publications into
separate data collection forms and combine these.
Assessment of risk of bias in included studies
Two review authors (GW, JG) will independently assess the risk
of bias of included studies with any disagreements resolved by
consensus with a third review author (KMac). We will use the
Cochrane EPOCGroup nine-point criteria for RCTs, non-RCTs,
and CBA studies (Cochrane EPOC Group 2013b):
1. sequence generation;
2. allocation concealment;
3. blinding, baseline characteristics;
4. baseline outcome measurement;
5. incomplete data outcome;
6. selective outcome reporting;
7. protection against contamination;
8. other reporting bias.
We will assess ITS studies using the seven standard Cochrane
EPOC Group criteria (Cochrane EPOC Group 2013b):
1. intervention independent of other changes;
2. pre-specified effect shape;
3. intervention unlikely to affect data collection;
4. blinding;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We will rate each component and categorise it in a ’Risk of bias
table’ as “low risk”, “unclear risk” or “high risk” as described inthe
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We will document for each included study a summary
assessment of the risk of bias.
Measures of treatment effect
We will record and report measures of effect in the same way
investigators have reported them. We will perform all analyses
using the Cochrane Collaboration’s statistical software, Review
Manager 2014, and record data in the form of a table included in
the Cochrane EPOCGroup’s data extraction template (Cochrane
EPOCGroup 2013a).Wewill report absolute differences and rele-
vant per cent differences between intervention and control groups
and the differences in the pre-post intervention change between
groups. For dichotomous outcomes after adjusting for baseline
differences, we will report risk ratios (RRs). For continuous data
we will report mean differences (MDs) between the intervention
and comparison group. For ITS studies, we will report regression
analysis with time trends before and after the intervention. If pos-
sible we will re-analyse data for ITS studies where there is inappro-
priate analysis or reporting of results using the methods described
in Ramsay 2003.
Unit of analysis issues
We will assess whether an appropriate adjustment has been made
for clustering in RCTs and CBA studies to avoid unit of analysis
errors. If there is insufficient data for re-analysis, we will attempt to
correct such errors by contacting authors to obtain additional data.
Where this is not possible and sufficient data exists, wewill perform
an approximate analysis and the P value will be annotated ’re-
analysed’. We will re-analyse inappropriately designed ITS studies
using time-series regression and report a statistical comparison of
time trends with a minimum of three data points before and after
the intervention.
Dealing with missing data
We will apply the risk of bias criteria to exclude studies with a
high risk of missing data as they pose serious threats to validity
(Higgins 2011). Where appropriate we will contact study authors
for further information. If this is not possible we will report the
data as missing. We will follow the principles of intention to treat
analyses as far as possible.
Assessment of heterogeneity
We may find that the range of healthcare settings, differing non-
medical prescribers, differing clinical conditions being managed
and variation in study designs will lead to clinical, methodological
and statistical heterogeneity. Assessment of these differences will
inform the analysis and determine whether results can be statis-
tically combined in a meta anaylsis.The review team will make
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this decision on a consensus basis. We will assess statistical hetero-
geneity by using the Chi2 test to assess if differences in results are
compatible with chance alone using a P value < 0.10. Statistical
heterogeneity will be quantified using the I2 statistic as appropri-
ate. We will determine that a high level of heterogeneity exists if I
2 is greater than 30%.
Assessment of reporting biases
We will assess the risk of publication bias based on the character-
istics of included studies. If there are sufficient studies, considera-
tion will be given to using funnel plots to assess risk of publication
bias.
Data synthesis
We will use a structured synthesis approach to analyses. We will
use a random-effects model should a meta-analysis be possible. For
any quantitative synthesis we will use Review Manager 2014 for
statistical analysis as appropriate. However, we anticipate the pri-
mary analyses will be quantitative anticipating explanatory factors
such as the variation in the range of non-medical prescribers, their
education, years of experience, location, practice setting and range
of clinical conditions being treated, will make it difficult to com-
bine intervention outcomes in a meta-analysis. We will include
key data elements such as explanatory factors, results, effects and
certainty of evidence in a table for each category of intervention.
Where it is not applicable to use the average effect across studies of
an intervention we will report interquartile ranges, range of effects
or plain language summaries as appropriate.
Subgroup analysis and investigation of heterogeneity
We will undertake the following subgroup analyses if sufficient
studies result in similar outcomes; however, it may not make sense
to calculate an average effect of non-medical prescribing across
these subgroups:
1. type of non-medical prescribers;
2. type of intervention;
3. type of setting (primary care, secondary care).
Explanatory factors e.g. level of education, location, patient con-
dition being treated, adherence to therapy and practice guidelines,
type of prescribing within and across sub groups may explain dif-
ferences in outcomes and limit the applicability of findings. Where
appropriate we will use visual displays e.g. analyses of tables or
bubble plots to explore the heterogeneity of results across studies.
We will use multivariate statistical analyses to examine how the
size of observed effects are related to the explanatory factors.
Sensitivity analysis
We will consider performing sensitivity analyses for missing data
by imputing a plausible range of assumptions and discussing the
implications of missing data. We will use sensitivity analyses to
assess the robustness of results including the impact of notable
assumptions and assess studies with a high or variable differing
risk of bias. Should meta-analysis be possible for the specified
outcomes, we will test the robustness of the overall results (and
conclusions) by excluding each study individually to determine its
effect. Where studies are combined with different scales we will
ensure that higher scores for continuous outcomes have the same
meaning. Wewill examine the impact of methodological decisions
such as reanalysis of data or the inclusion/exclusion of studies on
the stability of results.
Summary of findings
We will use a ’Summary of findings’ table to record results, out-
comes and outcome risks in our structured synthesis. In addition,
wewill use the fiveGrading of Recommendations Assessment,De-
velopment and Evaluation (GRADE) study considerations (study
limitations, consistency of effort, imprecision, indirectness and
publication bias) to assess the quality of the body of evidence and
summarise our confidence in the effects of the interventions by
outcome across studies .
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Appendix 1. MEDLINE search strategy (1946 to 8 April 2014)
# Searches Results
1 ((non-medical or non-medico) adj3 prescrib$).ti,ab. 93
2 (prescribing adj3 autonomy).ti,ab. 17
3 ((non-physician? or non-professional? or non-clinician) adj3
(prescribing or prescriber? or prescription? or “prescribed by”)
).ti,ab
7
4 ((prescribing adj2 (independen$ or collaborat$)) or indepen-
dent prescriber?).ti,ab
139
5 ((delegat$ adj10 prescribing) or (extend$ adj3 prescrib$ role?)
).ti,ab
8
6 (task? adj2 (shift or shifting or substitution) adj10 (prescribing
or prescriber?)).ti,ab
0
7 (prescrib$ adj3 (autonomy or autonomous$ or responsibilit$
or authority or right?)).ti,ab
409
8 (prescription? adj3 (autonomy or autonomous$ or responsi-
bilit$ or authority or right?)).ti,ab
188
9 ((nurse or nurses or nursing staff or non-clinician or non-physi-
cian? or allied health) and pharmacotherapy).ti
8
10 ((nurse or nurses) and prescrib$).ti. 511
11 ((role adj3 (change or substitut$)) and (prescriber? or prescrib-
ing)).ti,ab
10
12 ((task? adj2 (shift or shifting or substitution)) and (prescribing
or prescriber?)).ti,ab
4
13 ((allied health or ambulance or chiropractor? or counsel?or? or
dental assistant? or emergency vehicle? or emergency worker?
or health$ worker? or midwife? or midwives or non-clinical
or non-professional? or nurse or nurses or nursing staff or
paramedic? or pharmacist? or physical therapist? or physician?
assistant? or physician? extender? or physiotherapist? or podia-
trist? or psychologist?) adj3 (prescribing or prescriber?)).ti,ab
1093
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(Continued)
14 ((allied health or ambulance or chiropractor? or counsel?or? or
dental assistant? or emergency vehicle? or emergencyworker? or
health$ worker? or midwife? or midwives or nurse or nurses or
paramedic? or pharmacist? or physical therapist? or physician?
assistant? or physiotherapist? or podiatrist? or psychologist?)
adj3 prescription?).ti,ab
405
15 ((allied health or ambulance or chiropractor? or counsel?or? or
dental assistant? or emergency vehicle? or emergencyworker? or
health$ worker? or midwife? or midwives or nurse or nurses or
paramedic? or pharmacist? or physical therapist? or physician?
assistant? or physiotherapist? or podiatrist? or psychologist?)
adj3 ((adjust$ or alter$ or chang$ or decision$ or manage? or
management or managing) adj2 (dosage? or dose))).ti,ab
20
16 Drug Prescriptions/nu [Nursing] 218
17 (Pharmacist? and pharmacotherapy).ti. 27
18 ((nurse or nurses or nursing staff or pharmacist?) adj4 (phar-
maceutical care or drug therapy)).ti,ab
393
19 supplementary prescribing.ti,ab. 64
20 (prescrib$ adj2 team?).ti,ab. 26
21 or/1-20 [Keyword Set] 2703
22 allied health personnel/ or community health workers/ or emer-
gency medical technicians/ or home health aides/ or exp nurses’
aides/ or pharmacists’ aides/ or physical therapists/ or exp physi-
cian assistants/ or infection control practitioners/ or exp nurses/
or exp nursing staff/ or pharmacists/
152862
23 *allied health personnel/ or *community health workers/ or
*emergency * medical technicians/ or *home health aides/ or
exp *nurses’ aides/ or *pharmacists’ aides/ or *physical thera-
pists/ or exp *physician assistants/ or *infection control practi-
tioners/ or exp *nurses/ or exp *nursing staff/ or *pharmacists/
112094
24 (chiropractor? or counsel?or? or dental assistant? or emergency
vehicle? or emergency worker? or health$ worker? or midwife?
or midwives or nonphysician? or non-physician? or nurse or
nurses or paramedic? or pharmacist? or physical therapist? or
physician? assistant? or physiotherapist? or podiatrist? or psy-
chologist?).ti
112243
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(Continued)
25 ((chiropractor? or counsel?or? or dental assistant? or emergency
vehicle? or emergency worker? or health$ worker? or midwife?
or midwives or nonphysician? or non-physician? or nurse or
nurses or paramedic? or pharmacist? or physical therapist? or
physician? assistant? or physiotherapist? or podiatrist? or psy-
chologist?) adj5 ((role? adj2 (chang$ or new or newly)) or (re-
sponsibilit$ adj3 (chang$ or increas$ or new or newly)))).ab
458
26 (pharmacist-led or pharma$ initiated or ((driven or lead or led)
adj2 pharmacist?)).ti
113
27 (prescribing adj3 (authority or right?)).ti,ab. 144
28 (taskshifting or task shifting).ti,ab. 268
29 (delegat$ adj3 (authority or responsibility)).ti,ab. 408
30 ((nurse or nurses or nursing staff or non-clinician or non-physi-
cian? or allied health or pharmacist?) adj4 pharmacotherapy).
ti
14
31 or/22,24-30 [Allied Health Professionals--Broad] 217064
32 or/23-30 [Allied Health Professionals --Focussed] 182149
33 (prescribing or prescriber? or (prescription? adj3 (issue? or is-
suing or writing))).ti
9699
34 prescribing role?.ab. 40
35 (prescrib$ adj3 (autonomy or autonomous$ or responsibilit$
or authority or right?)).ti,ab
409
36 Drug Prescriptions/ 21831
37 *Prescriptions/ 947
38 Prescriptions/ and (dt or tu or th).fs. 678
39 Electronic Prescribing/ 503
40 Drug Dosage Calculations/ 955
41 (pharmacist-led or pharma$ initiated or ((driven or lead or led)
adj2 pharmacist?)).ti
113
42 Medication Therapy Management/ 653
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(Continued)
43 Drug Therapy/ 27809
44 or/33-43 [Prescribing/Drug Therapy terms] 56707
45 (randomized controlled trial or controlled clinical trial).pt. or
randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti
894174
46 exp animals/ not humans.sh. 3917953
47 45 not 46 [Cochrane RCT Filter 6.4.d Sens/Precision Maxi-
mizing]
825248
48 intervention?.ti. or (intervention? adj6 (clinician? or collabo-
rat$ or community or complex or DESIGN$ or doctor? or ed-
ucational or family doctor? or family physician? or family prac-
titioner? or financial or GP or general practice? or hospital? or
impact? or improv$ or individuali?e? or individuali?ing or in-
terdisciplin$ or multicomponent or multi-component or mul-
tidisciplin$ or multi-disciplin$ or multifacet$ or multi-facet$
or multimodal$ or multi-modal$ or personali?e? or personali?
ing or pharmacies or pharmacist? or pharmacy or physician? or
practitioner? or prescrib$ or prescription? or primary care or
professional$ or provider? or regulatory or regulatory or tailor$
or target$ or team$ or usual care)).ab
159444
49 (pre-intervention? or preintervention? or “pre intervention?” or
post-intervention? or postintervention? or “post intervention?
”).ti,ab. [added 2.4]
10010
50 (hospital$ or patient?).hw. and (study or studies or care or
health$ or practitioner? or provider? or physician? or nurse? or
nursing or doctor?).ti,hw
711695
51 demonstration project?.ti,ab. 1941
52 (pre-post or “pre test$” or pretest$ or posttest$ or “post test$”
or (pre adj5 post)).ti,ab
64885
53 (pre-workshop or post-workshop or (before adj3 workshop) or
(after adj3 workshop)).ti,ab
606
54 trial.ti. or ((study adj3 aim?) or “our study”).ab. 621001
55 (before adj10 (after or during)).ti,ab. 354106
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(Continued)
56 (“quasi-experiment$” or quasiexperiment$or “quasi random$”
or quasirandom$ or “quasi control$” or quasicontrol$ or (
(quasi$ or experimental) adj3 (method$ or study or trial or
design$))).ti,ab,hw
100401
57 (“time series” adj2 interrupt$).ti,ab,hw. 1025
58 (time points adj3 (over or multiple or three or four or five or six
or seven or eight or nine or ten or eleven or twelve or month$
or hour? or day? or “more than”)).ab
8951
59 pilot.ti. 39252
60 Pilot projects/ 81205
61 (clinical trial or controlled clinical trial or multicenter study).
pt
622190
62 (multicentre or multicenter or multi-centre or multi-center).ti 28689
63 random$.ti,ab. or controlled.ti. 747170
64 (control adj3 (area or cohort? or compare? or condition or de-
sign or group? or intervention? or participant? or study)).ab.
not (controlled clinical trial or randomized controlled trial).pt
405585
65 evaluation studies as topic/ or prospective studies/ or retrospec-
tive studies/ [Added Jan 2013]
942946
66 (utili?ation or programme or programmes).ti. [Added Jan
2013]
54298
67 (during adj5 period).ti,ab. [Added Jan 2013] 296950
68 ((strategy or strategies) adj2 (improv$ or education$)).ti,ab.
[Added Jan 2013]
18042
69 “comment on”.cm. or review.pt. or (review not “peer review$”)
.ti. or randomized controlled trial.pt. [Changed Jan 2013]
2887047
70 (rat or rats or cow or cows or chicken? or horse or horses or
mice or mouse or bovine or animal?).ti
1333989
71 exp animals/ not humans.sh. 3917953
72 (or/48-68) not (or/69-71) [EPOC Methods Filter 2.5-added
Evaluation Studies line forward--Jan 20130 Medline]
2792648
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(Continued)
73 review.pt. and (systematic.ti,ab. or (medline or embase or cinahl
or (search adj2 literature)).ab.)
83621
74 (((systematic or literature) adj2 review) or (metaanalysis or
meta-analysis)).ti
80056
75 or/73-74 [REview filter] 133986
76 21 and 75 [REviews] 69
77 21 [Keyword Strategy] 2703
78 (and/31,44) not 21 [Non-physicians & prescribing terms] 2835
79 (and/32,44) not 21 [Non-physicians & prescribing terms-fo-
cussed]
2080
80 (or/77-78) and 47 [RCT--export] 346
81 (and/72,77) not 80 [EPOC KW--export ] 978
82 (and/72,79) not (or/80-81) [EPOC MeSH --export] 768
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Johnson George (JG) and Greg Weeks (GW) devised the study and prepared the protocol which was reviewed by Derek Stewart (DS)
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The authors are researchers in the area of non-medical prescribing. While their studies may be referenced in the Review Background it
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